Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.

Condition:   High Risk Proliferative Diabetic Retinopathy
Interventions:   Procedure: Panretinal Photocoagulation (PRP);   Drug: Intravitreous injection of ranibizumab
Sponsors:   Association for Innovation and Biomedical Research on Light and Image;   Association for Innovation and Biomedical Research on Light and Image
Not yet recruiting – verified September 2013

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

  

  

  

4 + 2 =